ArticleCureus2025
Clear Cell Carcinoma of the Uterine Cervix in a 14-Year-Old Girl: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ovary Preservation for Cervical Clear Cell Adenocarcinoma in an 8-Year-Old Girl: A Novel Approach.Case reports in obstetrics and gynecology · 2026Article
- Retrospective analysis of treatment and prognosis for clear cell carcinoma of the uterine cervix: 15-year experience at a single institution.The journal of obstetrics and gynaecology research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clear cell carcinoma of the uterine cervix is a rare subtype. We report the case of a 14-year-old girl who presented with abnormal genital bleeding, a 7 cm mass arising from the uterine cervix, and swollen right inguinal lymph nodes. Histological and immunohistochemical examinations showed clear cell carcinoma. We performed a modified-radical hysterectomy, bilateral salpingo-oophorectomy, right inguinal lymph node biopsy, bilateral pelvic lymph node biopsy, and para-aortic lymph node biopsy, and diagnosed uterine cervical cancer stage IVB (clear cell carcinoma, pT2bN2M1). We administered paclitaxel-carboplatin+bevacizumab+pembrolizumab as adjuvant chemotherapy. Pembrolizumab is an immune checkpoint inhibitor associated with characteristic adverse events called immune-related adverse events (irAEs). In this case, arthritis and autoimmune pancreatitis were observed as irAEs during the treatment, but the patient was able to continue treatment. There is limited clinical experience with immune checkpoint inhibitors for pediatric patients. When remission is achieved, a better long-term prognosis is expected than in adults, so it is necessary to follow up with attention to late-onset irAEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.